Umgang mit NSAR bei der Behandlung der axialen SpondyloarthritisDealing with NSAID in the treatment of axial spondylarthritis

[1] Ramiro S(2023)ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update Ann Rheum Dis 82 19-34

[2] Nikiphorou E(2016)Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with Infliximab plus Naproxen as compared to Naproxen alone: results from the Infliximab as first line therapy in patients with early active axial Spondyloarthritis trial Arthritis Rheumatol 68 1899-1903

[3] Sepriano A(2017)Mechanism of new bone formation in axial spondyloarthritis Curr Rheumatol Rep 19 55-874

[4] Ortolan A(2019)Health care and disease burden in persons with axial spondyloarthritis in Germany Z Rheumatol 78 865-1925

[5] Webers C(2011)Increased mortality in ankylosing spondylitis is related to disease activity Ann Rheum Dis 70 1921-416

[6] Baraliakos X(2015)Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study Ann Intern Med 163 409-251

[7] Poddubnyy D(2011)ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis Ann Rheum Dis 70 249-3041

[8] Listing J(2015)Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) Cochrane Database Syst Rev 19 3031-938

[9] Brief Report SJ(2015)Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials Ann Rheum Dis 17 426-undefined

[10] Poddubnyy D(2020)Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials Exp Ther Med 58 929-undefined

[1] Ramiro S(2023)ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update Ann Rheum Dis 82 19-34

[2] Nikiphorou E(2016)Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with Infliximab plus Naproxen as compared to Naproxen alone: results from the Infliximab as first line therapy in patients with early active axial Spondyloarthritis trial Arthritis Rheumatol 68 1899-1903

[3] Sepriano A(2017)Mechanism of new bone formation in axial spondyloarthritis Curr Rheumatol Rep 19 55-874

[4] Ortolan A(2019)Health care and disease burden in persons with axial spondyloarthritis in Germany Z Rheumatol 78 865-1925

[5] Webers C(2011)Increased mortality in ankylosing spondylitis is related to disease activity Ann Rheum Dis 70 1921-416

[6] Baraliakos X(2015)Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study Ann Intern Med 163 409-251

[7] Poddubnyy D(2011)ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis Ann Rheum Dis 70 249-3041

[8] Listing J(2015)Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) Cochrane Database Syst Rev 19 3031-938

[9] Brief Report SJ(2015)Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials Ann Rheum Dis 17 426-undefined

[10] Poddubnyy D(2020)Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials Exp Ther Med 58 929-undefined